Research
Hormonal
Mechanical unloading, changes in adipokines (increased adiponectin, decreased leptin), and reduced estrogen levels are primary mechanisms driving bone loss during caloric restriction.
Understanding that bone loss is driven by hormonal and mechanical changes helps contextualize the risk. It is not necessarily 'damage' but an adaptation. Addressing it involves mimicking the mechanical load (exercise) and ensuring nutritional support (calcium/vitamin D) that the body might otherwise get from fat tissue.
GoodSupportsHIGH confidence
A probable contributor is the mechanical unloading of the skeleton with weight loss... Adiponectin, which is inversely associated with fat mass, stimulates osteoclast differentiation and action... A reduction in adiposity also decreases circulating estrogens, which are critical for bone integrity in men and women.
Why this rating
Supported by multiple citations of mechanistic studies in the paper.
Source
Decline in Bone Mass During Weight Loss: A Cause for Concern?
Anne L. Schafer · Journal of Bone and Mineral Research · 2015
DOI 10.1002/jbmr.2754
narrative_reviewCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Caloric restriction-induced weight loss in nonobese younger adults causes a significant decline in bone mineral density (BMD) at the spine and proximal femur, characterized by increased bone resorption and decreased bone formation.Good
- Exercise (particularly weight-bearing and muscle-loading) and higher protein intake can attenuate, but not prevent, the decline in bone mass associated with caloric restriction.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →